» Articles » PMID: 36587055

Identification of Common and Specific Genes Involved in Mouse Models of Age-Related and Cyclophosphamide-Induced Diminished Ovarian Reserve

Overview
Journal Reprod Sci
Publisher Springer
Date 2022 Dec 31
PMID 36587055
Authors
Affiliations
Soon will be listed here.
Abstract

Diminished ovarian reserve (DOR) is an etiologically heterogeneous disorder that usually leads to poor reproductive outcomes. Does a specific or common pathogenesis exist for DOR subtypes with different etiologies? Two frequently used mouse models, age-related DOR (AR-DOR) and cyclophosphamide (CTX)-induced DOR (CTX-DOR), were successfully established, and RNA sequencing was performed on ovarian tissue samples. Differentially expressed genes (DEGs) in each subtype and common DEGs (co-DEGs) in the two subtypes were identified. Subsequently, we performed comprehensive bioinformatics analyses, including an evaluation of immune cell infiltration. Finally, the genes of interest were further validated by performing RT-qPCR and immunohistochemistry. In AR-DOR mice, functional enrichment analyses showed that upregulated DEGs were mainly involved in the inflammatory/immune response, while downregulated DEGs were involved in DNA damage repair. In CTX-DOR mice, the inflammatory/immune response and cell apoptosis played significant roles. Meanwhile, 406 co-DEGs were identified from the two models. The biological functions of these co-DEGs were associated with inflammatory/immune responses. The analysis of immune cell infiltration showed reduced infiltration of Treg cells, as well as increased infiltration of M0 macrophages, NK resting, and T cells CD4 follicular in both DOR subtypes. The results of the validation experiments were consistent with the RNA sequencing data. In conclusion, the inflammatory/immune response might be the common pathogenesis for the two DOR subtypes, while DNA repair and cell apoptosis may have different roles in the two subtypes. These results may provide potential insights for mechanistic research and therapeutic targets of DOR.

Citing Articles

Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage.

Guo Y, Xue L, Tang W, Xiong J, Chen D, Dai Y Hum Reprod Update. 2024; 30(5):614-647.

PMID: 38942605 PMC: 11369228. DOI: 10.1093/humupd/dmae020.


Selenomethionine Inhibits NF-κB-mediated Inflammatory Responses of Bovine Mammary Epithelial Cells Caused by Klebsiella pneumoniae by Increasing Autophagic Flux.

Xu S, Miao Y, Dong J, Cui L, Liu K, Li J Biol Trace Elem Res. 2023; 202(4):1568-1581.

PMID: 37407885 DOI: 10.1007/s12011-023-03757-2.

References
1.
Fabregues F, Ferreri J, Mendez M, Calafell J, Otero J, Farre R . Follicular Activation and Stem Cell Therapy as a Novel Treatment Strategies in Diminished Ovarian Reserve and Primary Ovarian Insufficiency. Front Endocrinol (Lausanne). 2021; 11:617704. PMC: 7943854. DOI: 10.3389/fendo.2020.617704. View

2.
Jiao Z, Bukulmez O . Potential roles of experimental reproductive technologies in infertile women with diminished ovarian reserve. J Assist Reprod Genet. 2021; 38(10):2507-2517. PMC: 8581103. DOI: 10.1007/s10815-021-02246-6. View

3.
Levi A, Raynault M, Bergh P, Drews M, Miller B, Scott Jr R . Reproductive outcome in patients with diminished ovarian reserve. Fertil Steril. 2001; 76(4):666-9. DOI: 10.1016/s0015-0282(01)02017-9. View

4.
Christodoulaki A, Boel A, Tang M, De Roo C, Stoop D, Heindryckx B . Prospects of Germline Nuclear Transfer in Women With Diminished Ovarian Reserve. Front Endocrinol (Lausanne). 2021; 12:635370. PMC: 7937897. DOI: 10.3389/fendo.2021.635370. View

5.
Pastore L, Christianson M, Stelling J, Kearns W, Segars J . Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR. J Assist Reprod Genet. 2017; 35(1):17-23. PMC: 5758472. DOI: 10.1007/s10815-017-1058-4. View